While in systemic-onset juvenile arthritis (Still's disease) there is strong evidence supporting the role of innate immunity and IL-1β [7]; in AOSD the most strong finding suggestive of NLRP3 and IL-1β involvement is the clinical improvement with IL-1β inhibitors. This evidence concerns the gene NLRP3 and adult-onset Still disease.